The round was co-led by Norwest Venture Partners and the Medtech Convergence Fund, a SV Health Investors venture fund, with participation from Gingerbread Capital and Green D Ventures. The funding will support development and commercialization of Nanopath's biosensing platform that aims to transform how women's pelvic and gynecologic infections are diagnosed.

Nanopath is dedicated to improving health equity worldwide, starting with women's health. Nanopath's proprietary molecular diagnostic test takes a radically new approach to how clinicians measure and characterize human health. Through its novel biosensing technology, the company has the potential to enable fast, high-complexity tests to be performed in minutes and at the point-of-care, rather than in centralized laboratories. Nanopath's founders seek to improve the lives of women and other underserved populations, while simultaneously enhancing the lives of the Nanopath team members through purpose-driven work that helps to develop and deploy its products.